{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T10:30:28Z","timestamp":1775039428978,"version":"3.50.1"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":1209,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1093\/annonc\/mdw327","type":"journal-article","created":{"date-parts":[[2017,2,3]],"date-time":"2017-02-03T17:24:08Z","timestamp":1486142648000},"page":"v103-v110","source":"Crossref","is-referenced-by-count":321,"special_numbering":"S5","title":["Prevention and screening in BRCA mutation carriers and other breast\/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening"],"prefix":"10.1016","volume":"27","author":[{"given":"S.","family":"Paluch-Shimon","sequence":"first","affiliation":[]},{"given":"F.","family":"Cardoso","sequence":"additional","affiliation":[]},{"given":"C.","family":"Sessa","sequence":"additional","affiliation":[]},{"given":"J.","family":"Balmana","sequence":"additional","affiliation":[]},{"given":"M.J.","family":"Cardoso","sequence":"additional","affiliation":[]},{"given":"F.","family":"Gilbert","sequence":"additional","affiliation":[]},{"given":"E.","family":"Senkus","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdw327_bb0010","unstructured":"NCCN Clinical practice guidelines in oncology: genetic\/familial high risk assessment: breast & ovarian Version 2.2016 ed2016. www.nccn.org\/professionals\/physician_gls\/pdg\/genetics_screening.pdf (5 August 2016, date last accessed)."},{"key":"10.1093\/annonc\/mdw327_bb0015","unstructured":"Familial breast cancer: classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer. Cardiff (UK), 2013."},{"key":"10.1093\/annonc\/mdw327_bb0020","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2741\/4230","article-title":"The breast cancer susceptibility genes (BRCA) in breast and ovarian cancers","volume":"19","author":"Paul","year":"2014","journal-title":"Front Biosci (Landmark Ed)"},{"key":"10.1093\/annonc\/mdw327_bb0025","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.1088759","article-title":"Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2","volume":"302","author":"King","year":"2003","journal-title":"Science"},{"key":"10.1093\/annonc\/mdw327_bb0030","doi-asserted-by":"crossref","first-page":"18032","DOI":"10.1073\/pnas.1115052108","article-title":"Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing","volume":"108","author":"Walsh","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1093\/annonc\/mdw327_bb0035","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.29041","article-title":"Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian","volume":"121","author":"Mersch","year":"2015","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdw327_bb0040","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1086\/301749","article-title":"Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium","volume":"62","author":"Ford","year":"1998","journal-title":"Am J Hum Genet"},{"key":"10.1093\/annonc\/mdw327_bb0045","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/ng1096-185","article-title":"Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2","volume":"14","author":"Roa","year":"1996","journal-title":"Nat Genet"},{"key":"10.1093\/annonc\/mdw327_bb0050","doi-asserted-by":"crossref","first-page":"14205","DOI":"10.1073\/pnas.1415979111","article-title":"Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2","volume":"111","author":"Gabai-Kapara","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1093\/annonc\/mdw327_bb0055","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/jmg.2009.075176","article-title":"Risk of breast cancer in male BRCA2 carriers","volume":"47","author":"Evans","year":"2010","journal-title":"J Med Genet"},{"key":"10.1093\/annonc\/mdw327_bb0060","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1093\/jnci\/djm203","article-title":"Breast cancer risk among male BRCA1 and BRCA2 mutation carriers","volume":"99","author":"Tai","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdw327_bb0065","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jama.292.11.1317","article-title":"Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination","volume":"292","author":"Warner","year":"2004","journal-title":"JAMA"},{"key":"10.1093\/annonc\/mdw327_bb0070","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa031759","article-title":"Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition","volume":"351","author":"Kriege","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw327_bb0075","doi-asserted-by":"crossref","first-page":"8469","DOI":"10.1200\/JCO.2004.00.4960","article-title":"Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer","volume":"23","author":"Kuhl","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw327_bb0080","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2013.52.8331","article-title":"Effectiveness of screening with annual magnetic resonance imaging and mammography: results of the initial screen from the Ontario high risk breast screening program","volume":"32","author":"Chiarelli","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw327_bb0085","doi-asserted-by":"crossref","first-page":"e5660","DOI":"10.1136\/bmj.e5660","article-title":"Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1\/2 mutations: retrospective cohort study (GENE-RAD-RISK)","volume":"345","author":"Pijpe","year":"2012","journal-title":"BMJ"},{"key":"10.1093\/annonc\/mdw327_bb0090","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1200\/JCO.2012.47.8313","article-title":"Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"31","author":"Phillips","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw327_bb0095","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/S0140-6736(00)03258-X","article-title":"Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group","volume":"356","author":"Narod","year":"2000","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdw327_bb0100","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1056\/NEJM199901143400201","article-title":"Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer","volume":"340","author":"Hartmann","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw327_bb0105","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1093\/jnci\/93.21.1633","article-title":"Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers","volume":"93","author":"Hartmann","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdw327_bb0110","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1245\/s10434-007-9449-x","article-title":"Prophylactic mastectomy in BRCA1\/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic","volume":"14","author":"Heemskerk-Gerritsen","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"10.1093\/annonc\/mdw327_bb0115","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1056\/NEJM200107193450301","article-title":"Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation","volume":"345","author":"Meijers-Heijboer","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw327_bb0120","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1200\/JCO.2004.04.188","article-title":"Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group","volume":"22","author":"Rebbeck","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw327_bb0125","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.2010.1237","article-title":"Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality","volume":"304","author":"Domchek","year":"2010","journal-title":"JAMA"},{"key":"10.1093\/annonc\/mdw327_bb0130","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1136\/jmg.2008.062232","article-title":"Risk reducing mastectomy: outcomes in 10 European centres","volume":"46","author":"Evans","year":"2009","journal-title":"J Med Genet"},{"key":"10.1093\/annonc\/mdw327_bb0135","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1399-0004.2010.01604.x","article-title":"Breast cancer after bilateral risk-reducing mastectomy","volume":"79","author":"Skytte","year":"2011","journal-title":"Clin Genet"},{"key":"10.1093\/annonc\/mdw327_bb0140","doi-asserted-by":"crossref","first-page":"R110","DOI":"10.1186\/bcr3052","article-title":"Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1\/2","volume":"13","author":"Mulligan","year":"2011","journal-title":"Breast Cancer Res"},{"key":"10.1093\/annonc\/mdw327_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/bjs.6463","article-title":"Prophylactic mastectomy and the timing of breast reconstruction","volume":"96","author":"Morrow","year":"2009","journal-title":"Br J Surg"},{"key":"10.1093\/annonc\/mdw327_bb0150","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1524-4741.2011.01079.x","article-title":"Extended indications for nipple-sparing mastectomy","volume":"17","author":"Niemeyer","year":"2011","journal-title":"Breast J"},{"key":"10.1093\/annonc\/mdw327_bb0155","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.suronc.2008.03.004","article-title":"Nipple-sparing mastectomy: where are we now?","volume":"17","author":"Chung","year":"2008","journal-title":"Surg Oncol"},{"key":"10.1093\/annonc\/mdw327_bb0160","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s10549-009-0497-8","article-title":"Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab)","volume":"120","author":"Kiely","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdw327_bb0165","doi-asserted-by":"crossref","first-page":"g226","DOI":"10.1136\/bmj.g226","article-title":"Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis","volume":"348","author":"Metcalfe","year":"2014","journal-title":"BMJ"},{"key":"10.1093\/annonc\/mdw327_bb0170","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/ijc.29032","article-title":"Improved overall survival after contralateral risk-reducing mastectomy in BRCA1\/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis","volume":"136","author":"Heemskerk-Gerritsen","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/mdw327_bb0175","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1093\/jnci\/91.17.1475","article-title":"Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers","volume":"91","author":"Rebbeck","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdw327_bb0180","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/jnci\/djn442","article-title":"Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers","volume":"101","author":"Rebbeck","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdw327_bb0185","doi-asserted-by":"crossref","first-page":"djv033","DOI":"10.1093\/jnci\/djv033","article-title":"Breast cancer risk after salpingo-oophorectomy in healthy BRCA1\/2 mutation carriers: revisiting the evidence for risk reduction","volume":"107","author":"Heemskerk-Gerritsen","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdw327_bb0190","doi-asserted-by":"crossref","first-page":"dju091","DOI":"10.1093\/jnci\/dju091","article-title":"Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis","volume":"106","author":"Friebel","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdw327_bb0195","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1200\/JCO.2014.59.4945","article-title":"Risk algorithm using serial biomarker measurements doubles the number of screen-detected cancers compared with a single-threshold rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening","volume":"33","author":"Menon","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw327_bb0200","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1158\/1055-9965.EPI-07-2703","article-title":"A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study","volume":"17","author":"Greene","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1093\/annonc\/mdw327_bb0205","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.2013.53.2820","article-title":"Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation","volume":"32","author":"Finch","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw327_bb0210","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12905-014-0150-5","article-title":"Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers","volume":"14","author":"Marchetti","year":"2014","journal-title":"BMC Womens Health"},{"key":"10.1093\/annonc\/mdw327_bb0215","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11864-016-0396-2","article-title":"Options in prophylactic surgery to prevent ovarian cancer in high-risk women: how new hypotheses of fallopian tube origin influence recommendations","volume":"17","author":"Swanson","year":"2016","journal-title":"Curr Treat Options Oncol"},{"key":"10.1093\/annonc\/mdw327_bb0220","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.fertnstert.2015.07.1162","article-title":"BRCA mutation carriers show normal ovarian response in in vitro fertilization cycles","volume":"104","author":"Shapira","year":"2015","journal-title":"Fert Steril"},{"issue":"Suppl. 6","key":"10.1093\/annonc\/mdw327_bb0225","doi-asserted-by":"crossref","first-page":"vi160","DOI":"10.1093\/annonc\/mdt199","article-title":"Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Peccatori","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw327_bb0230","doi-asserted-by":"crossref","first-page":"7804","DOI":"10.1200\/JCO.2004.00.8151","article-title":"Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group","volume":"23","author":"Rebbeck","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw327_bb0235","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3109\/13697137.2014.947254","article-title":"Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels","volume":"18","author":"Santen","year":"2015","journal-title":"Climacteric"},{"issue":"Suppl. 3","key":"10.1093\/annonc\/mdw327_bb0240","doi-asserted-by":"crossref","first-page":"iii124","DOI":"10.1093\/annonc\/mdu103","article-title":"Bone health in cancer patients: ESMO Clinical Practice Guidelines","volume":"25","author":"Coleman","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdw327_bb0245","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/gutjnl-2012-303108","article-title":"International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer","volume":"62","author":"Canto","year":"2013","journal-title":"Gut"},{"key":"10.1093\/annonc\/mdw327_bb0250","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1056\/NEJMsr1501341","article-title":"Gene-panel sequencing and the prediction of breast-cancer risk","volume":"372","author":"Easton","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw327_bb0255","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1001\/jama.2014.5985","article-title":"Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer","volume":"313","author":"Rebbeck","year":"2015","journal-title":"JAMA"},{"key":"10.1093\/annonc\/mdw327_bb0260","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1086\/321805","article-title":"Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients","volume":"33","author":"Dykewicz","year":"2001","journal-title":"Clin Infect Dis"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341931645X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341931645X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/27\/suppl_5\/v103\/6679012\/mdw327.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T23:49:06Z","timestamp":1749944946000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375341931645X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":51,"alternative-id":["S092375341931645X"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdw327","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]}}}